Portfolio Companies News
January 10, 2018GenSight Biologics receives MHRA ap...
Paris, France, January 10, 2018, 7.30 am CET – GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, announced UK ... read more
January 9, 2018Pulmonx Submits Premarket Approval ...
Zephyr EBVs are the Only Minimally-Invasive, Removable Devices for Emphysema with Validated Diagnostic Tool to Select Patients Likely to Benefit from Treatment REDWOOD CITY, Calif. – January 9, 2018 – Pulmonx® Corp. today announced its filing of a Premarket Approval (PMA) application with ... read more
January 9, 2018BioClin Therapeutics Appoints Graem...
(San Ramon, California, January 9, 2018) BioClin Therapeutics, Inc.(BioClin), a privately-held clinical stage biotechnology company developing a first-in-class anti-FGFR3 (fibroblast growth factor receptor 3) monoclonal antibody to treat solid tumors, specifically metastatic bladder cancer, announce... read more
January 8, 2018Targovax announces the appointment ...
Oslo, Norway, 8 January 2018: Targovax ASA ("Targovax" or "the Company"; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, announces that Michael Bogenstaetter has been appointed as the Company's Chief Business Officer (CBO). He will take... read more
January 6, 2018Nexstim enrols last patient in supp...
06 January 2018 Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company"), a medical technology company developing and marketing pioneering navigated non-invasive brain stimulation systems for both therapeutic and diagnostic applications, announces that it has successfully completed enrolment i... read more
November 13, 2017Q3 2017 General Market Overview
Since the start in 1996, HealthCap funds have invested in 110 portfolio companies.
41 of the portfolio companies have been taken public on nine different markets.
24 of the portfolio companies’ pharmaceutical products have been approved for marketing.
Since the start in 1996, HealthCap has helped build 7 companies with a valuation of USD 1 billion or more and 35 companies with a valuation of SEK 1 billion or more.